TCR gene transfer: MAGE-C2/HLA-A2 and MAGE-A3/HLA-DP4 epitopes as melanoma-specific immune targets by Straetemans, Trudy et al.
Hindawi Publishing Corporation
Clinical and Developmental Immunology
Volume 2012, Article ID 586314, 14 pages
doi:10.1155/2012/586314
Research Article
TCR Gene Transfer: MAGE-C2/HLA-A2 and MAGE-A3/HLA-DP4
Epitopes as Melanoma-Specific Immune Targets
Trudy Straetemans,1 Mandy van Brakel,1 Sabine van Steenbergen,1
Marieke Broertjes,1 Joost Drexhage,1 Joost Hegmans,2 Bart N. Lambrecht,2
Cor Lamers,1 Pierre van Der Bruggen,3 Pierre G. Coulie,3 and Reno Debets1
1 Laboratory of Experimental Tumor Immunology, Department of Medical Oncology, Erasmus MC, 3015 GE,
Rotterdam, The Netherlands
2Department of Pulmonary Diseases, Erasmus MC, 3015 GE, Rotterdam, The Netherlands
3Ludwig Institute for Cancer Research Ltd, Brussels Branch, and de Duve Institute, Universite´ Catholique de Louvain,
1200 Brussels, Belgium
Correspondence should be addressed to Reno Debets, j.debets@erasmusmc.nl
Received 25 July 2011; Revised 7 October 2011; Accepted 20 October 2011
Academic Editor: Tetsuya Nakatsura
Copyright © 2012 Trudy Straetemans et al. This is an open access article distributed under the Creative Commons Attribution
License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly
cited.
Adoptive therapy with TCR gene-engineered T cells provides an attractive and feasible treatment option for cancer patients.
Further development of TCR gene therapy requires the implementation of T-cell target epitopes that prevent “on-target” reactivity
towards healthy tissues and at the same time direct a clinically eﬀective response towards tumor tissues. Candidate epitopes
that meet these criteria are MAGE-C2336−344/HLA-A2 (MC2/A2) and MAGE-A3243−258/HLA-DP4 (MA3/DP4). We molecularly
characterized TCRαβ genes of an MC2/A2-specific CD8 and MA3/DP4-specific CD4 T-cell clone derived from melanoma
patients who responded clinically to MAGE vaccination. We identified MC2/A2 and MA3/DP4-specific TCR-Vα3/Vβ28 and TCR-
Vα38/Vβ2 chains and validated these TCRs in vitro upon gene transfer into primary human T cells. The MC2 and MA3 TCR were
surface-expressed and mediated CD8 T-cell functions towards melanoma cell lines and CD4 T-cell functions towards dendritic
cells, respectively. We intend to start testing these MAGE-specific TCRs in phase I clinical trial.
1. Introduction
Adoptive therapy with antigen-specific T cells has shown
clinical successes in the treatment of viral infections and
tumors [1–5]. Receptor gene therapy, in which patients are
treated with gene-engineered T cells with either chimeric
antigen receptors (CARs) or T-cell receptors (TCRs), pro-
vides an attractive alternative to provide therapeutic immu-
nity. Clinical application of gene-engineered T cells to treat
various tumor types, such as renal cell cancer, ovarian cancer,
neuroblastoma, lymphoma, melanoma, and colorectal and
synovial cancers proved feasible but, despite some successes,
generally did not show antitumour responses in a substantial
number of patients [6–13]. Notably, in an early clinical trial
to treat metastatic renal cell cancer with CAR-engineered
T cells, with total T-cell doses as low as 2 × 108 T cells,
we observed reversible yet discrete cholangitis and damage
to bile duct epithelium as a likely consequence of T-cell
localization and expression of the target epitope carbonic
anhydrase IX (CAIX) on normal tissue [6]. Subsequent trials
with CARs directed against Her2/Neu and CD19 and TCRs
directed against the HLA-A2-restricted antigens MARTI,
gp100 and CEA, have confirmed this notion [11, 12, 14, 15].
Collectively, these studies underscore the need for T-cell
target epitopes that are expressed on malignant tissue in a
highly restricted manner and are able to initiate a clinically
eﬀective T-cell response.
Cancer testis antigens (CTAs) are immunogenic proteins
expressed in many tumors but silenced in normal cells
except for male germline cells, placenta, and thymic
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medullary epithelial cells [16, 17]. In vitro studies have
provided initial proof that gene transfer of TCRαβ directed
against MAGE-A1/HLA-A1, MAGE-A3/HLA-A2, and NY-
ESO-1/HLA-A2 as well as NY-ESO-1/HLA-DP4 result in
eﬀective and CTA-specific T-cell responses [18–21]. Of the
group of CTA, in particular the MAGE antigens constitute
attractive candidates for immune therapy giving not only
tumour-specific expression but also their role in tumour
biology, expression in multiple tumours, and potential to
constitute eﬀective T-cell targets. Four families of MAGE
genes are located on chromosome X: MAGE-A (12 genes),
B (6 genes), C (4 genes), and D (2 genes). Up to now, there
are over 50 identified combinations of MAGE peptides
and HLA class I or class II molecules, recognized by CD8
or CD4 T cells, respectively (see for an overview: http://
cancerimmunity.org/peptidedatabase/Tcellepitopes.htm).
We propose the MAGE-C2336–344/HLA-A2 (MC2/A2)
peptide ALKVDVEERV and MAGE-A3243–258/HLA-DP4
(MA3/DP4) peptide KKLLTQHFVQENYLEY as candidate
T-cell targets for the following reasons. First, MC2 and
MA3 proteins actively contribute to the development of
malignancies. MC2 suppresses p53-dependent apoptosis,
thus prolonging tumor survival [22, 23], whereas MA3
mediates fibronectin-controlled progression and metastasis
[24], and is expressed by melanoma stem cells [25, 26].
Second, MC2 and MA3 are expressed in multiple tumor
types and their expression is associated with poor clinical
outcome in these tumor types [27–32]. MC2 is expressed
in 43% of metastatic melanomas, 33% of head and neck
squamous cell cancers, 30% of bladder cancers, and 10% of
nonsmall cell lung cancers [28]. MA3 is expressed in 76% of
metastatic melanomas [27], in up to 50% of nonsmall cell
lung cancer [29], and in many other tumor types such as
colon rectal, hepatocyte cellular, prostate and breast cancers,
and haematological malignancies such as multiple myeloma
[30, 33–36]. Furthermore, HLA-A2 and HLA-DP4 are the
most frequent MHC class I and II alleles among Caucasians,
that is, representing 44 and 75% of the general population,
respectively. And third, MC2 and MA3 potentially constitute
clinically eﬀective T-cell target epitopes, as evidenced by
induction of enhanced numbers of anti-MAGE T cells
that paralleled significant and durable clinical responses
[37, 38].
The clinical potential of MC2-specific T cells is exempli-
fied by a high frequency of MC2/A2-specific CTL (10−4 of
CD8 T cells) observed in the blood of a melanoma patient
whose tumors regressed after vaccination with MAGE-A1
and A3 peptides, whereas in the same patient the frequency
of anti-vaccine CTLs was low (3 × 10−6 of CD8 T cells)
[37]. A CTL clone recognizing this epitope (EB81-CTL16)
was isolated demonstrating the most pronounced increase in
frequency not only in blood but also in a regressing cuta-
neous metastasis (>100 and 1000-fold, resp.). Interestingly,
the same patient also showed increased frequencies in blood
and a regressing metastasis (up to 200-fold) of other T-cell
clones-specific for the same and other MC2 epitopes [39]. In
a second melanoma patient who showed tumor regression
upon MAGE vaccination, the most frequent antitumor
CTL clone was again directed against a MC2 epitope [40].
With respect to MA3, various trials have been performed
substantiating its clinical potential as a T-cell target. A
phase II clinical trial with highly purified MA3 protein in
nonsmall cell lung cancer showed a significant reduction
in relative risk of cancer recurrence following surgery in
vaccinated versus placebo-treated patients [41]. This MA3
vaccine provided B-cell responses, CD8 T-cell responses as
well as HLA-DP4-restricted CD4 T-cell responses against the
MA3 KKL epitope in lung cancer patients [42, 43]. Recently,
a phase III trial started to investigate the eﬃcacy of MA3
antigen vaccination after tumor resection in lung cancer
patients [44]. Also in melanoma patients, MA3 protein
vaccinations using either protein or MA3-expressing PBMC
initiate antigen-specific immune responses [45]. Vaccina-
tions with dendritic cells loaded with MA3/DP4 peptide
rapidly induced peptide-specific T-helper-cell responses in
melanoma patients. Median survival in vaccinated patients
was longer than in untreated control patients and showed
no signs of major toxicities due to vaccination [46]
and personal communication (Gerold Schuler, Erlangen,
Germany).
In this study, we chose MC2336–344/A2 and MA3243–258/
DP4 as T-cell epitopes, and cloned and characterized
the corresponding TCRαβ genes of CD8 and CD4 T-cell
clones derived from two metastatic melanoma patients who
responded clinically to MAGE-vaccination. TCRαβ genes
were then introduced into primary human T cells, and tested
for surface expression and MAGE-specific CD8 and CD4 T-
cell functions in vitro.
2. Materials and Methods
2.1. Melanoma Patients EB81 and R12 and Patient-Derived
T-Cell Clones. In a vaccination study, metastatic melanoma
patient EB81 received cutaneous vaccinations with recom-
binant canarypox (ALVAC) virus, carrying a minigene
encoding antigenic MAGE-A1 and A3 peptides that are
presented by HLA-A1. These were followed by vaccinations
with the same peptides. One year after the first vaccination,
all cutaneous metastases had disappeared, and the patient
remained tumor-free for 3 years [37]. CTL-606C/22.2 (EB81-
CTL 16) is a cytotoxic CD8 T-cell clone derived from EB81
whose increase in frequency is most pronounced in various
body compartments upon vaccination with MAGE, and
it recognizes MC2336–344/HLA-A2 (ALKVDVEERV) [37].
Melanoma patient 12 was included in a clinical trial in which
mature monocyte-derived dendritic cells loaded with multi-
HLA class I and II peptides (including MAGE-A3243–258
peptide) were administered subcutaneously [38]. CD4
T-cell clone R12-C9, recognizing MA3243–258/HLA-DP4
(KKLLTQHFVQENYLEY), was derived from PBMC from
melanoma patient 12, after in vitro stimulation with
MA3243–258/DP4 peptide and sorted on IFNγ secreting CD4+
T cells by FACSVantage flow cytometer (BD Biosciences)
as described earlier [46]. CTL clones 16 and R12-C9 were
cultured in IMDM with 10% human serum, glutamine, and
antibiotics.
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2.2. Other Cells and General Reagents. PBMC from healthy
donors were isolated by centrifugation through Ficoll-
Isopaque (density = 1.077 g/cm3; Amersham Pharmacia
Biotech, Uppsala, Sweden). Transduced primary human T
cells were cultured in RPMI 1640 medium supplemented
with 25mM HEPES, 200mM L-glutamine, 10% human
serum, antibiotics, and 360 IU/mL human rIL-2 (Proleukin;
Chiron, Amsterdam, The Netherlands) and stimulated every
2 weeks with a mixture of irradiated allogeneic feeder
cells as described elsewhere [47]. The human embryonic
kidney cell line 293T and Phoenix-Ampho, both used to
package retroviruses carrying RNA encoding TCRαβ, were
grown in DMEM with 10% fetal bovine serum (FBS;
Greiner Bio-one Alphen a/d Rijn, The Netherlands), glu-
tamine, antibiotics, and 1% MEM nonessential amino
acids. The same medium plus supplements was used to
grow the melanoma cell lines EB-81-MEL-2 (MC2/A2pos)
and MZ2-MEL43 (MA3/DP4pos). An MC2neg/A2pos and
MA3neg/DP4pos B lymphoblast cell line (BSM) and an
EBV transformed HLA-DP4pos B cell line (i.e., EBV-MAGJ)
transduced with retrovirus encoding li-MA3 cDNA as
described in [48] (i.e., EBV-MA3) were cultured in RPMI
supplemented with glutamine, antibiotics, and 10% FBS.
The melanoma cell line EB-81-MEL-2 and the B cell line
EBV-MAGJ were derived from the same patients from
whom the T-cell clones were derived (melanoma patient
EB-81 and patient 12, resp.). In some cases, target cells
were pretreated with 50 pg/mL human recombinant IFNγ
(Peprotech, Rocky Hill, NJ, USA) for 48 h prior to functional
T-cell assays.
MC2/A2 peptideMHC (pMHC) complexes were ordered
from Proimmune (Oxford, UK). MA3/DP4 pMHC com-
plexes were produced in S2-drosophila insect cells, essentially
as described previously [46]. We used the following mAbs:
anti-CD4 (clone 13 B8.2, BD Biosciences, Erembodegem,
Belgium), anti-CD8 (clone SK1, BD Biosciences) and anti-
TCR-Vβ2 mAbs (clone MPB 2D5, Immunotech, Marseille,
France). Other reagents used were the HLA-A2-binding
peptides MC2336–344 (ALKVDVEERV) and (as a control)
gp100280–288 (YLEPGPVTA), the HLA-DP4-binding peptide
MA3243–258 (KKLLTQHFVQENYLEY) (all three from Euro-
gentec, Maastricht, The Netherlands), Phytohemagglutinin
(PHA) (Remel Ltd, Lenexa, KS, USA), Phorbol 12-Myristate
13-Acetate (PMA) (Sigma-Aldrich, St. Louis, MO, USA),
GM-CSF, IL-4, TNFα (all three from PeproTech) and PGE2
(Sigma-Aldrich).
2.3. MAGE-A3 Protein. MA3 protein was expressed by the
Des insect cell expression system (Invitrogen, Breda, The
Netherlands). To this end, MA3 cDNA was cloned into the
pMT/BiP/V5-His vector and, together with the pCoHygro
vector, introduced into S2-insect cells by nucleofection
(Amaxa Biosystems, Cologne, Germany) according to the
manufacturer’s guidelines. MA3 protein expression by trans-
fected S2 cells, at a density of 3 × 106/mL, was induced by
copper sulfate (500 μM). Five days after induction of protein
expression, culture medium was harvested and soluble MA3
protein was purified by FPLC (Acta, GE Healthcare, Zeist,
The Netherlands) using a histrap column, followed by size
exclusion on a sephadex 75 column.
2.4. Genes Encoding TCRαβ-Specific for MC2/A2 and
MA3/DP4. RNA was isolated from T-cell clones EB81-
CTL16 and R12-C9 and reverseLy transcribed with Super-
script III (Invitrogen) according to the manufacturer’s
instructions. The TCR-Vα and Vβ regions were amplified
and family-typed using a set of sense primers, covering all
variable segments, in combination with either a TCR-Cα or
Cβ antisense consensus primer. Nested PCR was performed
on TCR-Vα and Vβ products before gel electrophoresis.
Primers specific for Cβ1 or Cβ2 were used to discriminate
between both Cβ genes. Positive PCR products were cloned,
and plasmid DNAs from at least 5 independent colonies were
sequenced. Specific primers were then used to amplify full-
length (FL) TCRα and β DNAs from CTL-derived cDNA. In
some cases, (i.e., MA3/DP4 TCRβ) primers were also used
to amplify control TCR DNAs from a spleen cDNA library.
Standard primers were used to amplify the TCRα and TCRβ
DNAs and will be provided upon request. TCRα and β genes
were cloned as wild-type TCRs into two separate pBullet
retroviral vectors [49] (abbreviated as pB: TCRα+β) or as
codon-optimized TCRs in a TCRβ-2A-TCRα cassette in a
single pMP71 vector (abbreviated as pMP71: optTCRβ-2A-
TCRα, see Supplementary text and figures available online
at doi: 10.1155/2012/586314). The strategy we employed to
clone MAGE-specific TCRαβ genes and to test their surface
expression and function following TCR gene transfer is
depicted in Figure 1(a).
2.5. Transduction of Human T Lymphocytes. Human T
lymphocytes of healthy donors were activated with anti-
CD3 mAb and transduced with retrovirus harboring either
MAGE-specific or control TCRα and β transgenes. The trans-
duction procedure was described by Lamers and colleagues
[50] except that in the current study TCR-encoding retro-
viruses were produced by a coculture of 293T and Phoenix-
Ampho packaging cells. T cells were FACSorted using the
corresponding p/MHC multimer prior to functional assays.
For some experiments, theMA3/DP4 TCR transduced T cells
were depleted either for CD4 or CD8 T cells using anti-CD4
or CD8 mAb-coated and PE-labeled magnetic beads and
MACS columns (Miltenyi, Bergisch Gladbach, Germany)
according to the manufacturer’s instructions.
2.6. Flow Cytometry of TCR-Transduced T Lymphocytes.
MC2/A2 TCR-transduced T cells were analyzed for TCR
expression by flow cytometry using PE-labeled MC2/A2
pentamers (10 nM). MA3/DP4 TCR-transduced T cells were
analyzed for TCR expression by PE-labeled anti-TCR-Vβ2
mAb, PE-labeled MA3/DP4 tetramers (50 nM), and anti-
CD4 mAb. For immunostaining, 0.5 × 106 transduced T
cells were washed with PBS and incubated with MC2/A2
pentamer (or antibodies) at 4◦C for 30min or with
MA3/DP4 tetramer at 37◦C for 2 h. Upon completion of
the immunostainings, cells were washed and fixed with
1% paraformaldehyde. Events were acquired and analyzed
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A     V     R       S      P      I       G     F  V      L     P     H     I      Q  W    S       S
GCTGTGAGGTCTCCGATAGGCTTT GTTTTACCACATATCCAG TGGTCCAGC
 TGTGCTTACACGGTTCCCTCTAATGCTGGT GTCCATCCAAATATCCAG TGGTCCAGC
C      A     Y      T      V      P      S     N     A      G V      H     P     N     I      Q W     S      S
T      V     V     E      D      L S       R     G
ACCGTTGTAGAGGACCTG TCCAGAGGC
(b)
Figure 1: Cloning and validation of MC2/A2 and MA3/DP4 TCRαβ genes. (a) Schematic representation of how TCR DNAs have been
cloned, typed for TCR-V(D)J gene usage, and tested in T cells following gene transfer. (b) TCR-V(D)J and C classification of the TCRα
and β chains expressed by EB81-CTL16 and R12-C9 according to http://www.imgt.org/. The arrow before the Jα6.01 indicates a frame shift
preventing surface expression of this TCR-Vα2 chain. Sequence data for human TCR-Vα2, Vα3, and Vβ28 of EB81-CTL16-derived TCR
genes are available from GenBank under accession nos. EU427373, EU427374, and EU427375, respectively; and sequence data for human
TCR-Vα38 and Vβ22 of R12-C9-derived TCR genes are available fromGenBank under accession nos. EU427376 and EU427377, respectively.
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on a Cytomics FC 500 flow cytometer with CXP software
(Beckman Coulter, Mijdrecht, The Netherlands).
2.7. Cytotoxicity Assay. Cytotoxic activity of T cells was
measured in a standard 6 h 51Cr-release assay as described
previously [51]. Peptide loading of target cells was performed
by addition of either MC2, gp100 (control) or MA3 peptide
(final concentrations at 10 μM) for 15min at 37◦C and 5%
CO2 prior to cocultivation with eﬀector T cells.
2.8. Cytokine Production. To quantify the production of
cytokines after antigen-specific stimulation, 6 × 106 T cells
were cultured in the presence of 2×106 target cells for 18 h at
37◦C and 5% CO2. As a positive control, T-cell transductants
were stimulated with PHA and PMA. Supernatants were
harvested, and levels of IFN-γ and TNF-α were determined
by standard ELISA (Sanquin, Amsterdam, The Netherlands).
2.9. CD4 T-Cell Assay. CD4 T-cell assays were based on
dendritic cell: CD4 T-cell cocultures. To generate autologous
dendritic cells (DCs), we used PBMC from the same
HLA-DP4-positive donor that had been used to generate
MA3/DP4 TCR-transduced CD4 T cells. PBMCwere MACS-
enriched using CD14 microbeads (Miltenyi Biotech), seeded
at 106 cells/mL in RPMI 1640 medium without HEPES
and supplemented with glutamine, 10% FBS, 10 μg/mL
gentamycine, and the cytokines GM-CSF (1000 IU/mL) and
IL-4 (200 IU/mL). At day 6, cells were used as a source of
immature DC and incubated with MA3 protein (25 μg/mL)
either in the absence or presence of TNFα (200 IU/mL) and
PGE2 (5 μM) for an additional 2 days resulting in immature
or mature MA3-positive DC, respectively. DC maturation
state was confirmed by flow cytometric analysis of surface
expression of CD80, CD86, and HLA-DR.
Immature ormatureMA3-positive DCs were washed and
added at 2 × 104 per round-bottomed microwell to 2 × 105
CD4 T cells in 200 μl T-cell medium. After 4 days of DC:
T-cell coculture, supernatants were harvested, and cytokine
production was determined in culture supernatants with
Cytokine Bead Array (Th1/Th2 CBA kit, BD Biosciences)
according to the manufacturer’s instructions.
3. Results
3.1. Sequences of TCRαβ Genes from MAGE-Specific T-
Cell Clones. CD8 T-cell clone EB81-CTL16 and CD4 T-
cell clone R12-C9, which were established from melanoma
patients following MAGE vaccinations, were used to
obtain genes encoding for MC2/A2- and MA3/DP4-specific
TCRαβ’s. Sequence characterization revealed that EB81-
CTL 16 harbored genes encoding TCR-Vα2.01/Jα6.01/Cα,
Vα3.01/Jα35.01/Cα, and Vβ28.01/Jβ1-6.01/Cβ1, whereas
R12-C9 harbored genes encoding TCR-Vα38.02/Jα52.01/Cα
and Vβ2.01/Dβ1.01/Jβ1-2.01/Cβ2. We found that the TCR-
Vα2.01/Jα6.01/Cα contained a frame shift in the Jα region
(Figure 1(b)). As a result, there was a premature stop codon
in the constant domain and no surface expression of this
TCRα chain (see Figure 2(a)). Figure 1(b) shows the exact
nucleotide and amino acid sequences of the various MAGE
TCR chains and their corresponding TCR-V(D)J and C
classifications (according to http://www.imgt.org/).
3.2. TCR-Vα3/Vβ28 Chains Confer T Cells with the Ability
to Bind MC2336–344/A2 Ligands. Retroviral transduction of
human primary T cells with the TCR-Vα3Cα and Vβ28Cβ1
chains but not with irrelevant TCRα and β chains (i.e.,
mock TCR) resulted in TCR surface expression and binding
to multimers of recombinant HLA-A2 molecules folded
with MC2336–344 peptide (Figure 2(a)). Enrichment of TCR-
transduced T cells (TCR T cells) with MC2/A2 multimers by
FACSort resulted in higher proportions of T cells expressing
the MC2/A2 TCR (30% versus 65% pMHC binding before
and after sort, Figure 2(b)). TCR surface expression was
stable for at least three months (data not shown).
3.3. TCR-Vα3/Vβ28-Transduced Primary Human T Cells
Show Antigen-Specific Functions In Vitro. To assess the
antigen-specific cytolytic function of MC2/A2 TCR T cells,
T cells were cocultured with the MC2/A2-positive tumor cell
line, EB81-MEL-2. Figure 3(a) shows that if these tumor cells
were pretreated with IFNγ, they were lysed by the TCR T
cells. MC2 peptide-loaded HLA-A2 positive B cells (BSM)
were lysed very eﬃciently, whereas gp100 peptide-loaded B
cells were not recognized. Additionally, TCR T cells produced
IFNγ but not TNFα in response to IFNγ pretreated EB81-
MEL-2 cells, although T cells produced both IFNγ and TNFα
in response to MC2 peptide-loaded cells (Figure 3(b)). No
IFNγ was produced by MC2/A2 TCR T cells in response to
MC2pos/A2neg tumor cells (Supplementary Figure 1(b)).
3.4. TCR-Vα38/Vβ2 Chains Provide T Cells with the Abil-
ity to Bind MA3243–258/HLA-DP4 Ligands. MA3/DP4 TCR-
transduced T cells, whether depleted or not for either
the CD4 or CD8 T-cell subset, expressed high lev-
els of TCR-Vβ2 (Figure 4(a)). Sorting the T cells after
gene transfer for high-pMHC binding resulted in expres-
sions that improved by a factor of two (21 and 26%
pMHC binding prior to sorting versus 48 and 44%
post sorting for CD4 and CD8-depleted T cells, resp.)
(see Figure 4(b)). Mock T cells did not bind MA3/DP4
pMHC multimers. Similar to the MC2/A2 TCR, MA3/DP4
TCR expression was stable for at least three months
(data not shown).
3.5. MA3/DP4 TCR T Cells Recognize Antigen-Positive B Cells
but Not Melanoma Cells Natively Expressing MA3 Antigen.
MA3/DP4 TCR T cells specifically lysed MA3/DP4 positive
EBV B cells (EBV-MA3) (Figure 5(a)). Depleting MA3/DP4
TCR T cells for CD8 T cells resulted in CD4 T cells with
a cytotoxic capacity similar to that of nondepleted T cells
(mainly being of the CD8 T-cell subset). T cells transduced
with the TCRβ chain of the MA3/DP4 TCR and a TCRα
chain from a human spleen cDNA library served as a negative
control (referred to as Mock T cells) and did not lyse MA3-
positive B cells (Figure 5(a)). MA3/DP4 TCR T cells did not
lyse MZ2-MEL43 melanoma cells, which naturally express
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Figure 2: Primary human T cells transduced with TCR-Vα3/Vβ28 genes bind MC2/A2 pMHC. The MC2/A2 TCR T cells were labeled
with PE-conjugated MC2336–344/A2 pentamers before flow cytometric analysis (solid lines). (a) T cells transduced either with TCR-
Vα2Cα/Vβ28Cβ1 and Vα3Cα/Vβ28Cβ1 or control TCRαβ genes (Mock), and not sorted for MC2/A2 binding. (b) T cells transduced with
TCR-Vα3Cα/Vβ28Cβ1 genes and FAC Sorted with MC2/A2 pentamer. Results are from a representative transduction out of 6 transductions
of PBMC from 2 donors with similar results.
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Figure 3: MC2/A2 TCR is functionally expressed by primary human T cells. (a) MC2/A2 TCR T cells lyse MC2/A2 positive target cells. TCR
T cells were tested in a 6 h 51Cr-release assay. The following target cells were used: MC2/A2-positive EB81-MEL-2 melanoma cells (derived
from the same patient from whom the MC2 TCR was derived), pretreated or not with IFNγ, and A2-positive BSM EBV-B cells, pulsed either
with gp100 or MC2 peptide (both at 10 μM final). Mock T cells did not lyse MC2/A2-positive target cells (data not shown). Eﬀector-to-
target cell ratios are indicated on the x-axis and specific 51Cr-releases are indicated on the y-axis. (b) MC2/A2 TCR T cells produce cytokines
upon coculture with MC2/A2-positive target cells. T-cell production of IFNγ and TNFα (in pg/mL) was measured by ELISA in supernatants
harvested after an 18 h coculture between T cells and the target cells described in legend to Figure (a) No cytokines were produced by T cells
only or Mock T cells cocultured with MC2-positive target cells (data not shown). Measurements were performed in triplicate and expressed
as mean values corrected for medium values. Data shown are from representative experiments out of 4 experiments from 2 donors with
similar results.
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Figure 4: Surface expression of MA3/DP4 TCR on human primary T cells following gene transfer. Human primary T cells transduced with
MA3/DP4 TCRαβ genes were stained with TCR-Vβ2 mAb (in which case nonstained MA3/DP4 TCR T cells served as a negative control
since control TCRαβ genes also comprise the TCR-Vβ2 chain) (a) or MA3/DP4 tetramer (b) prior to analysis by flow cytometry. In (a), the
following T cells were analyzed: parental CD4 T-cell clone R12-C9; TCR T cells, nondepleted (bulk) and TCR T cells depleted for either
CD8 or CD4 T cells. These T-cell populations are not FAC sorted. In (b), TCR-transduced T cells, depleted for either CD8 or CD4 T cells
nonsorted, or FAC sorted with MA3/DP4 tetramer, were analyzed. Results are from a representative transduction out of 4 transductions of
PBMC from 2 donors with similar results.
theMA3/DP4 antigen (Figure 5(b)). Pretreatment with IFNγ
did not, but addition of MA3 peptide did, enhance killing of
the MZ2-MEL43 melanoma cells by MA3/DP4 TCR T cells
(Figures 5(c) and 5(d)). Next, we showed that MA3/DP4
TCR T cells, but not Mock T cells, produced IFNγ and to
a lesser extent TNFα in response to EBV-MA3 cells, with
CD4 T cells as the predominant source of both cytokines
(Figure 6(a)). It is noteworthy that TCR CD4 T cells,
but not the parental R12-C9 T-cell clone, produced more
IFNγ than TNFα (Figure 6(a)). Responses of TCR T cells
towards EBV-MA3 B cells were blocked with an anti-TCR
Vβ2 antibody, whereas those towards MA3pos/DP4neg tumor
cells (Supplementary Figure 2(b)) and MA3neg/DP4pos B cells
were always negative (data not shown). T cells expressing
MA3/DP4 TCR (but not Mock) were able to respond to
MZ2-MEL43 melanoma cells only when target cells were
preloaded with MA3 16mer peptide; this demonstrates that
these melanoma cells can be sensitized to peptide-specific T-
cell functions (i.e., cytotoxicity: data not shown; production
of IFNγ and TNFα: Figure 6(b)).
3.6. MA3/DP4 TCR CD4 T Cells Produce Cytokines upon
Coculture with MA3-Loaded Autologous Monocyte-Derived
DC. Since MA3/DP4 TCR T cells are unable to directly
recognize antigen-positive melanoma cells, an ability that
is generally expected only for antitumor CD8 T cells, we
analyzed a more typical CD4 T-cell response that is based
on (cross-) presentation of tumor antigens by DC. To this
end, MA3/DP4 TCR and Mock CD4 T cells were cocultured
with immature or mature DC derived from autologous
monocytes using two diﬀerent MA3 protein concentrations
for DC uptake. After 4 days, the production of various
cytokines was determined in supernatants of the DC: T-cell
cocultures. Upon coculture with the MA3-protein-loaded
DC, MA3/DP4 TCR CD4 T cells (but not Mock CD4 T cells)
produced significant amounts of IFNγ (up to 1300 pg/mL)
and to a lesser extent TNFα, IL-2, IL-4, and IL-5 (Figure 7).
MA3-specific production of IL-10 was negligible. T-cell
cytokine production was negligible or absent when either
nonprotein-loaded immature or mature DC or Mock T cells
were used.
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Figure 5: MA3/DP4 TCR T cells specifically lyse MA3-transduced or peptide-loaded B cells, but not MA3-positive melanoma cells. (a)
MA3/DP4 TCR T cells specifically lyse DP4-positive B cells transduced with MA3-encoding cDNA. Human T cells were tested in a 6 h
51Cr-release assay using EBV-MA3 target cells. The following eﬀector T cells were used: CD4 T-cell clone R12-C9, MA3/DP4 TCR T cells,
nondepleted T cells, MA3/DP4 TCR T cells depleted for CD8 T cells, or Mock T cells depleted for CD8 T cells. MA3-negative, DP4-positive B
cells (BSM) were not recognized by MA3/DP4 TCR T cells (data not shown). (b) MA3/DP4 TCR T cells do not lyse MZ2-MEL43 melanoma
cells, natively expressing MA3 and DP4. Eﬀector T cells used were those described in legend to Figure (a). (c) MA3/DP4 TCR T cells do
not lyse MZ2-MEL43 melanoma cells that are pretreated with IFNγ. Target cells were MZ2-MEL43 cells that were either pretreated with
IFNγ or not, and eﬀector T cells were MA3/DP4 TCR or Mock T cells. (d) MA3/DP4 TCR T cells lyse MZ2-MEL43 melanoma cells that are
pulsed with MA3 peptide. Target cells were MZ2-MEL43 cells that were either pulsed with MA3 peptide or not, and eﬀector T cells were
MA3/DP4 TCR T cells. Measurements were performed in triplicate and expressed as mean values corrected for medium values. Data are
from representative experiments out of 3 experiments with similar results.
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Figure 6: MA3/DP4 TCR T cells specifically produce IFNγ and TNFα upon coculture with MA3-transduced or peptide-loaded B cells, but
not MA3-positive melanoma cells. Cytokine production is determined in supernatants of T cells after an 18 h co-culture with (a) DP4-
positive B cells transduced with Ii-MA3 cDNA (EBV-MA3) or (b) MZ2-MEL43 cells loaded with MA3 peptide or not. In (a), eﬀector T
cells were: the CD4 T-cell clone R12-C9; MA3/DP4 TCR or Mock T cells, either nondepleted or depleted for CD8 T cells. MA3-negative,
DP4-positive B cells (such BSM) were not recognized by MA3/DP4 TCR T cells (data not shown). In (b), MA3/DP4 TCR or Mock T cells,
non-depleted, were used as eﬀector T cells. Supernatants were harvested and analyzed for IFNγ and TNFα by ELISA. Measurements were
performed in triplicate and expressed as mean values corrected for medium values. Data are from representative experiments out of 3
experiments with similar results.
4. Discussion
Redirection of T cells towards tumor-specific yet clinically
safe antigens holds great promise for the treatment of
melanoma and other tumor types. In the current paper,
we have studied MAGE-C2/HLA-A2 (MC2/A2) and MAGE-
A3/HLA-DP4 (MA3/DP4) as targets of TCR T cells; besides
being prevalent in the patient population, these antigens
are uniquely expressed by tumors and have proven value in
initiating clinically eﬀective CD8 and CD4 T-cell responses
[23, 27, 28, 46].
MC2/A2 and MA3/DP4 TCRαβ genes were derived from
T-cell clones obtained from MAGE-vaccinated patients and
were subsequently characterized following TCR gene transfer
(see Figure 1). The CD8 T-cell clone EB81-CTL 16 expressed
the MC2/A2-specific TCR-Vα3 and TCR-Vβ28 chains. Upon
gene transfer, primary human T cells bound pMHC and
demonstrated MC2-specific T-cell functions. TCR T cells
killed and produced IFNγ and TNFα upon coculture not
only with MC2 peptide-pulsed HLA-A2-positive target cells
but also native MC2-positive, HLA-A2-positive melanoma
cells (see Figures 2 and 3). T-cell responsiveness towards
native MC2-positive, HLA-A2-positive melanoma cells (i.e.,
EB81-MEL-2 cells) was enhanced by IFNγ pretreatment,
which promotes antigen processing and surface expression of
MHC and adhesionmolecules. In fact, unlike other antigenic
peptides, the MC2 epitope ALKDVEERV (i.e., MC2336–344)
requires immune proteasomes for proper processing and
presentation to T cells [52], supporting the value of MC2/A2
as a target for T-cell therapy. The eﬀective dose of MC2/A2
peptide at which CD8 T cells demonstrate a half-maximal
lytic response (i.e., ED50) is 0.75 nM [53]. This value repre-
sents a measure of T-cell avidity and lags somewhat behind
in comparison to reported values for T cells expressing other
MHC class I TCRs (range: 30–100 pM) [54, 55], suggesting
a lower-to-intermediate ligand-binding aﬃnity of this TCR.
Experiments with mutated pMHC complexes that either
prevent or enhance CD8α binding (according to [56, 57];
kindly provided by Professor Dr. Andrew Sewell, University
of Cardiﬀ, Wales) confirm the CD8-dependency of this MC2
TCR (data not shown).
The CD4 T-cell clone R12-C9 expressed the MA3/DP4
specific TCR-Vα38 and TCR-Vβ2 chains, which upon gene
transfer in primary human T cells, resulted in pMHC
binding (see Figure 4). In addition, MA3/DP4 TCR T cells,
containing both CD8 and CD4 T cells (i.e., nondepleted),
specifically lysed and produced IFNγ and TNFα upon
coculture with B cells either transduced with MA3 antigen
(Figures 5(a) and 6(b)) or loaded with MA3 peptide (data
not shown). The extent of lysis, a typical measure for CD8
T cell function, was lowered when testing MA3/DP4 TCR
CD4 T cells (i.e., depleted for CD8-positive T cells). The
responsiveness of MA3/DP4 TCR T cells towards MZ2-
MEL43 cells, generally weak and not reproducible, was not
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enhanced by IFNγ pretreatment of target cells, whereas T
cells were clearly able to recognize melanoma cells following
loading with the MA3 16-mer peptide but not a core 12-
mer peptide (TQGFVQENYLEY, i.e., MA3247–258) (Figures
5(b), 5(c), 5(d), and 6(b)). Collectively, these data argue
that MA3, like other nuclear proteins, may be ineﬃciently
presented by tumor cells, and T-cell responses directed to
tumor cells natively expressing MA3, such as those reported
for T-cell clones 22 and R12–57 [58, 59] are rare and
diﬃcult to reproduce. In fact, when screening a panel of
23 T-cell clones including many patient R12-derived T-cell
clones, we were unable to identify a single T-cell clone that
responded towards MZ2-MEL43 (data not shown). In this
respect, it is noteworthy that R12-derived CD4 T-cell clones
show a polyclonal response towards MA3/DP4, with 50% of
clonotypes sharing TCR-Vβ12 gene [46]. Thus, MA3/DP4
TCR T cells are able to lyse antigen-positive target cells,
but lysis becomes suboptimal in case (low levels of) antigen
is presented by tumor cells. The ED50 value of MA3/DP4
peptide in a CD4 T cell IFNγ assay is 30 nM [59]. This value
is in accordance with reported values for T cells expressing
other MHC class II TCRs (range: 40–200 nM) [20, 60].
Notably, functional expressions of MHC class II TCRs, such
as reported for NY-ESO-1/DP4 TCR, may depend on the
presence of the CD4 coreceptor [20], and are assessed by
typical CD4 T cell assays, such as T cell proliferation and
cytokine production. In case of MA3/DP4 TCR, we also
observed that antigen-specific IFNγ production is higher in
T cells depleted for CD8 T cells (i.e., CD4 T cells) when
compared to nondepleted T cells (i.e., CD4+ CD8 T cells,
Figure 6(a)).
Antitumor responses more typical for CD4 T cells are
induced by professional antigen-presenting cells, such as DC
(reviewed in [61]). DC capture and process tumor antigens
and cross-present MHC class II-restricted antigens to CD4 T
cells. Following activation, these CD4 T cells provide signals
to DC that enhance antigen presentation and costimulation
(via cross-linking of CD40) and lead to priming of antigen-
specific CD8 CTL function [62]. Importantly, activated CD4
T cells are a major source of IFNγ, an eﬀector cytokine with
potent tumor regressing activity via inhibition of tumor-
induced angiogenesis or activation of tumor-infiltrating
macrophages [63–65]. When analyzing DC-induced T-cell
responses, we observed significant production of cytokines
when immature or mature DC were loaded with MA3 pro-
tein and used to stimulate TCR T cells (Figure 7). Decreasing
the MA3 protein concentration during maturation of the
DC from 25 to 5 μg/mL resulted in only slightly lower but
almost comparable cytokine responses (data not shown).
These findings extend the observations with two other MHC
class II-restricted TCRs specific for human antigens, that
is, NY-ESO1/DP4 and DBY/DQ5 [20, 66]. MA3/DP4 TCR-
transduced T cells produced high amounts of IFNγ, whereas
TNFα, IL-2, IL-4, and IL-5 were produced to a lesser extent.
IL-10 represents the only cytokine with production levels
being low (<20 pg/mL) and not diﬀerent from TCR and
Mock-transduced T cells (Figure 7). In addition, coculture
with MA3-positive DC resulted in upregulated expression
of T-cell activation markers such as CD25 (IL-2Rα chain)
as well as enhanced T-cell proliferation (data not shown).
Analysis of DC phenotype and function after coculture with
MA3/DP4 TCRT cells was not possible, since DC died at days
1 and 2 after the start of coculture and were completely lost
at day 4, which was evidenced by light microscopy and lack
of IL-12 production and suggested direct killing of DC by
TCR T cells. Our observation that MA3/DP4-specific CD4
T cells recognize MA3-protein-loaded DC rather than MZ2-
MEL43 melanoma cells implies that these CD4 T cells yield
antitumor activity in vivo following cross-presentation by
professional antigen presenting cells. The therapeutic benefit
of antigen-specific IFNγ production have initiated studies
in which CD4 T cells were used as recipient T cells for
MHC class I-restricted TCR. Not only can CD4 T cells be
functionally endowed with MHC I-restricted TCR via gene
transfer [19, 67, 68], but also can genetic cointroduction
of CD8α skew TCR-engineered T cells towards an antigen-
specific Th1 type T-cell response [69]. Vice versa, the
introduction of a MHC class II TCR and CD4 coreceptor
in CD8 T cells may lead to the generation of T cells with
combined helper and eﬀector T-cell functions [66].
In extension to our results with wild type MC2 and
MA3 TCRs, we have tested gene optimization, a transgene
cassette and another retroviral vector to enhance functional
expression of TCR transgenes [70–72]. To this end, we have
cloned codon-optimized MC2 and MA3 TCRs in TCRβ-2A-
TCRα cassette-containing pMP71 vectors and demonstrated
significant TCR surface expression and MAGE-specific IFNγ
production by CD3 mAb-activated and transduced PBMC
(note that results with pMP71: optTCRβ-2A-TCRα reflect
bulk, nonsorted T cells, Supplementary Figures 1 and 2). In
preparation of clinical studies, we propose the following
additional strategies to enhance the therapeutic eﬃcacy
of T cells gene engineered with MC2 and MA3 TCRs.
First, administration of common γ-cytokines, such as a
combination of IL-15 and IL-21, to cultures of TCR T
cells prior to patient infusion will yield T cells that show
limited T-cell diﬀerentiation, and are better equipped to
persist and function in vivo ([73]; Lamers, manuscript
in preparation). Second, we propose preconditioning of
patients that, apart from nonmyeloablative treatment with
cyclophosphamide and fludarabine [1], includes treatment
with the DNA hypomethylating agent 5-AZA-CdR. Such
treatment, already used clinically, is reported to enhance
expression of MAGE antigens and HLA in melanoma [26,
74]. And third, cotreatment with MC2 TCR-transduced CD8
and MA3 TCR CD4 T cells may be of particular interest to
boost antitumor immunity and counteract selected growth
of epitope-negative tumor variants. In fact, we have recently
demonstrated that single-epitope targeting of melanoma by
TCR-engineered T cells results in highly eﬀective but tran-
sient regression in HLA-A2 transgenic mice and that more
eﬀective strategies likely require multi-epitope targeting
(Straetemans, manuscript submitted). The proposed dual-
epitope targeting approach may prove especially eﬀective
for CTA epitopes because of their coregulated expression
pattern in tumor cells, with the vast majority of tumor
cells expressing two or more CTAs [75]. Testing of cell lines
derived from tumors other thanmelanoma has started in our
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Figure 7: MA3/DP4 TCR CD4 T cells produce cytokines upon coculture with MA3 protein-loaded autologous dendritic cells. MA3/DP4
TCR, and Mock CD4 T cells were cultured with immature or mature autologous dendritic cells that were either loaded with 25 μg/mL MA3
protein or not. After 4 days, supernatants were harvested and analyzed for cytokine production by cytokine bead arrays. Cytokine production
was not detected in case T cells were cultured without dendritic cells (data not shown). Measurements were performed in duplicate and
expressed as mean values. Data are from a representative experiment out of 2 experiments with similar results.
laboratory, and may provide a preclinical rationale to extend
the proposed treatment to nonmelanoma tumors.
In short, we have cloned and in vitro validated two
MAGE-specific TCRs that warrant clinical testing in TCR
gene therapy in melanoma patients and in other patients
with cancers expressing the MC2 and MA3 antigens.
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